Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Clinical trial NCT03916627 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03916627
Sponsor: Regeneron Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Hepatocellular Carcinoma Head and Neck Squamous Cell Carcinoma

Start date: 2019-07-23
Primary completion: 2025-03-31
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.